Bio-Rad Laboratories, INC.: management transactions · United States · SEC (Form 4)

About Bio-Rad Laboratories, INC.

Bio-Rad Laboratories, Inc. is a U.S.-based life sciences and clinical diagnostics company listed on the NYSE/NASDAQ under the tickers BIO and BIO.B. Headquartered in Hercules, California, in the United States, the company was founded in 1952 in Berkeley by David and Alice Schwartz. Over time, Bio-Rad has built a reputation as a specialized provider of laboratory tools, diagnostics, and quality-control solutions, serving both research and clinical end markets. The business is organized into two core segments. Life Science supplies instruments, software, consumables, and reagents used to separate, purify, characterize, and quantify biological materials such as cells, proteins, and nucleic acids. These products are sold to universities, research institutes, pharmaceutical and biotechnology companies, and industrial laboratories, with additional use cases in biomanufacturing, process quality control, food safety, and science education. Clinical Diagnostics provides in vitro diagnostic products, including quality-control systems, blood typing and transfusion products, electrophoresis platforms, and solutions used in hospital and reference laboratories. The segment also has exposure to diabetes monitoring and other routine diagnostic workflows. Bio-Rad has a global operating footprint across research, manufacturing, and sales, giving it broad geographic reach and access to customers in North America, Europe, Asia, and other international markets. Its competitive position is shaped by technical specialization, a recurring consumables base, and long-standing relationships with laboratory and clinical customers. In many of its end markets, it competes with larger diversified healthcare and life science players such as Thermo Fisher, Danaher, Roche, Abbott, and other niche diagnostic specialists, depending on the product category. Bio-Rad’s differentiation lies in its depth in analytical tools, immunohematology, quality control, and advanced molecular workflows. Recent company updates in 2025 have highlighted mixed end-market conditions. Management has pointed to a tougher academic and biotech funding environment affecting Life Science, while Clinical Diagnostics has shown a more normalized growth profile. Bio-Rad has also emphasized strategic moves in digital PCR, including acquisition-led expansion and platform rollout, as well as partnerships aimed at oncology-related in vitro diagnostic applications. For investors, Bio-Rad stands out as a specialized, innovation-driven healthcare tools company with exposure to scientific research spending, diagnostic testing demand, and high-value recurring laboratory workflows in the United States and abroad.